Literature DB >> 12424535

Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.

M H J Van Oers1, A Hagenbeek, M Van Glabbeke, I Teodorovic.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12424535     DOI： 10.1007/s00277-002-0548-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Immunotherapy with rituximab in follicular lymphomas.

Authors:  Carmen Saguna; Ileana Delia Mut; Anca Roxana Lupu; Mihaela Tevet; Horia Bumbea; Cornel Dragan
Journal:  Maedica (Buchar)       Date:  2011-04

Review 2.  New developments in immunotherapy for non-Hodgkin's lymphoma.

Authors:  John P Leonard; Richard R Furman; Jia Ruan; Morton Coleman
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

Review 3.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Risto S Cvetković; Caroline M Perry
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Cost effectiveness of rituximab maintenance therapy in follicular lymphoma: long-term economic evaluation.

Authors:  Eric Deconinck; Houda Miadi-Fargier; Claude Le Pen; Pauline Brice
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.